Author

C. D. Klein

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

L. N. van Oosten· 1 shared M. A. Behnam· 1 shared M. A. M. Behnam· 1 shared M. M. Leuthold· 1 shared N. Kuehl· 1 shared T. Drazic· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 6 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

L. N. van Oosten

Author profile →

3 papers

Recent·Most cited

Alternate recognition by dengue protease: Proteolytic and binding assays provide functional evidence beyond an induced-fit

M. A. M. Behnam, C. D. Klein

The paper provides functional evidence that dengue protease recognizes substrates and inhibitors primarily through conformational selection rather than induced-fit, highlighting the impact of experimental conditions on ligand binding and proteolysis.

bioRxiv · Apr 15, 2024Biochemistry

Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay

T. Drazic, N. Kuehl, M. M. Leuthold, M. A. Behnam, C. D. Klein

The paper optimizes a FRET assay for SARS-CoV-2 Mpro, identifies new substrates, and improves catalytic efficacy through amino acid modifications.

bioRxiv · Feb 19, 2021Biochemistry

PhenoMS-ML: Phenotypic Screening by Mass Spectrometry and Machine Learning

L. N. van Oosten, C. D. Klein

PhenoMS-ML uses mass spectrometry and machine learning to identify and classify the mode of action of unknown antibacterial agents in bacterial cultures.

bioRxiv · Mar 30, 2019 · PreprintPharmacology & Toxicology